The CDG asks for your consent: We would like to process your pseudonymised data about the use of the website for analysis purposes in order to understand how visitors use our website so that we can make it even better and more intuitive. We use the open-source software Matomo for this purpose. By clicking on "accept all" you can give us your consent for this. You can revoke your consent at any time with effect for the future. You can withdraw your consent at any time by clicking the button "Customise cookie settings" and unchecking the "Analyse" box. The legality of the processing carried out up to that point is not affected by the cancellation.
Without your consent, we will only process your data to the extent technically necessary to display the website to you. Information on the required data processing and the technically required cookies can be found after clicking on the "Settings" button under "Required cookies" and in our privacy policy.
CD Laboratory for Innovative Allergy Therapeutics
Allergies are a global health problem affecting hundreds of millions of people. Allergic individuals have developed a so-called adaptive type 2 immune response to mostly harmless proteins, known as aller-gens. Allergen-specific antibodies of the immunoglobulin E class (IgEs) play a key role in this process.
IgEs bind to mast cells via a specific receptor called FcεRI. Mast cells are specialised immune cells with cytoplasmic granules filled with inflammatory mediators. When exposed to allergens, IgE-sensitised mast cells are activated and immediately release the granule-stored substances (degranu-lation). This mediator release causes the typical symptoms we know as allergic reactions, ranging from itching and sneezing to anaphylactic shock. Mast cells are therefore a central cause of allergies.
This CD Laboratory therefore aims to perform high-quality basic research on mast cells, investigating their biology and attempting to iden-tify new therapeutic approaches through the integration of state-of-the-art technologies. The main objective is to enable new therapies for patients with allergies or other mast cell-mediated diseases.